We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRML:NASDAQCritical Metals Corp. Analysis

Data as of 2026-09-01 - not real-time

$7.10

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Critical Metals Corp. trades at $7.10, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. It has gained 11.8% over the past 30 days. With RSI at 50.4 the momentum picture is neutral, alongside a bullish MACD signal. The recent range runs from support at $5.68 up to resistance at $8.56.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 83.1% above where the shares trade now. Revenue is growing at 57.8%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 123.9%, a beta of 4.21 and a maximum drawdown of 82.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top Market Events

European Lithium's US$835M merger with Critical Metals advances; final share ratio depends on CRML'sThe mechanics of the upcoming tie-up between European Lithium and Critical Metals Corp just became a lot more...European Lithium has updated its merger terms with Critical Metals, introducing a floating share ratio and targeting...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 9.72
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 9.72
  • Analyst targets imply +83.1% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +83.1% versus the current price
  • Negative return on equity of -141.0%
  • Revenue growth of +57.8%

Key Metrics & Analysis

Financial Health

Revenue Growth57.80%
P/E Ratio-37.4
ROE-140.98%
ROA-15.65%
Debt/Equity1.65
P/B Ratio6.0
Op. Cash Flow$-31071168
Free Cash Flow$52.1M

Technical Analysis

TrendBearish
RSI50.4
Support$5.68
Resistance$8.56
MA 20$6.90
MA 50$7.34
MA 200$9.72
MACDBullish
VolumeIncreasing
Fear & Greed Index94.04

Valuation

Fair Value$12.85
Target Price$13.00
Upside/Downside83.10%
GradeFair
TypeGrowth

Risk Assessment

Beta4.21
Volatility123.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.